1039 related articles for article (PubMed ID: 17094916)
1. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
2. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
3. Role of tissue factor in hepatocellular carcinoma genesis, invasion and metastasis.
Zhou Q; Huang T; Wang YF; Zhou XB; Liang LJ; Peng BG
Chin Med J (Engl); 2011 Nov; 124(22):3746-51. PubMed ID: 22340235
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
5. [Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis].
Zheng Q; Tang Z; Wu Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):57-9. PubMed ID: 10921061
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
Morita Y; Hayashi Y; Wang Y; Kanamaru T; Suzuki S; Kawasaki K; Ohta K; Yamamoto M; Saitoh Y; Itoh H; Doe WF
Hepatology; 1997 Apr; 25(4):856-61. PubMed ID: 9096588
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
8. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
9. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
10. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
11. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
13. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
15. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
16. [Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis].
Wang WC; Wang Y; Sun CJ
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):257-60. PubMed ID: 12536699
[TBL] [Abstract][Full Text] [Related]
17. [The expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma].
Liu Y; Chen X; Peng S; Fang H; Wu Y; Peng C; Shi L; Bai M; Xu B; Wang J; Deng G
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1553-6. PubMed ID: 12609066
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma].
Zheng Q; Tang Z; Wu Z; Shi D; Song H
Zhonghua Wai Ke Za Zhi; 1998 Aug; 36(8):474-6. PubMed ID: 11825444
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Taniguchi T; Kakkar AK; Tuddenham EG; Williamson RC; Lemoine NR
Cancer Res; 1998 Oct; 58(19):4461-7. PubMed ID: 9766679
[TBL] [Abstract][Full Text] [Related]
20. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]